---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007807"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:43:19.549233+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vericel reports FY2023 revenue $197.5M (+20% YoY); Q4 revenue $65.0M; FY2024 guidance $237-241M

## Summary
- Q4 net income $13.0M ($0.26 diluted EPS) vs $5.9M in Q4 2022, up 119%.
- FY2023 net loss narrowed to $3.2M from $16.7M; adjusted EBITDA $33.9M (+40%).
- MACI net revenue grew 22% to $56.7M in Q4; Burn Care revenue up 31% to $8.3M.
- FY2024 total revenue guidance $237-241M; gross margin ~70%; adj. EBITDA margin ~20%.
- Cash and investments $152.6M, zero debt; MACI arthroscopic delivery submission accepted by FDA.

## SEC filing metadata
- accession: 0001628280-24-007807
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828024007807/0001628280-24-007807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828024007807/vcel-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007807
- JSON: https://secwatch.observer/filing/0001628280-24-007807.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.